Personalized PTH Compound Administration Systems

A next-generation system for treating hypoparathyroidism, leveraging wearable devices, machine learning, and bioresponsive polymers to optimize PTH compound administration and improve patient outcomes.

The original patent relates to PTH compounds with low peak-to-trough ratios for treating hypoparathyroidism. However, the current approach relies on fixed administration intervals, which may not account for individual patient variability. The new inventive concept addresses this limitation by introducing personalized, adaptive, and responsive PTH compound administration systems.

The inventive concept comprises a wearable device configured to administer a PTH compound in a pulsatile manner, with a machine learning algorithm predicting optimal administration intervals based on individual patient data. Additionally, a bioresponsive polymer releases the PTH compound in response to changes in blood calcium levels, ensuring a peak-to-trough ratio of less than 4 within one administration interval at a steady state. The system may also include a device for transdermal administration of the PTH compound, with a built-in sensor for monitoring blood calcium levels and adjusting the administration rate accordingly.

The new claims introduce a paradigm shift in PTH compound administration by incorporating wearable devices, machine learning, and bioresponsive polymers. These innovations enable personalized, adaptive, and responsive treatment regimens, which are not anticipated by the original patent.

Alternative embodiments may include implantable devices, oral formulations with responsive coatings, or other routes of administration. Variations may involve different machine learning algorithms, polymer compositions, or sensor technologies.

The inventive concept has significant commercial potential in the pharmaceutical and medical device industries, targeting the growing market for personalized medicine and hypoparathyroidism treatment.